Upgrade to SI Premium - Free Trial

Mizuho Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)

June 26, 2026 8:09 AM
Mizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst commented: "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments